Skip to main content
Helixmith Co., Ltd logo

Helixmith Co., Ltd — Investor Relations & Filings

Ticker · 084990 ISIN · KR7084990001 KO Manufacturing
Open in API
Filings indexed 508 across all filing types
Latest filing 2024-01-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 084990

About Helixmith Co., Ltd

https://www.helixmith.com/

Helixmith is a biotechnology company specializing in the research and development of gene therapies. Established in 1996, the company focuses on creating innovative biopharmaceuticals for diseases with significant unmet medical needs. Its core activities revolve around an extensive pipeline of next-generation gene therapy products. The primary therapeutic areas of focus include neurological and cardiovascular disorders, such as peripheral artery disease and coronary artery disease. Helixmith manages a comprehensive range of capabilities, from discovery and preclinical studies to clinical development of its drug candidates.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by Bio Solution Co., Ltd. in Helixmith Co., Ltd., crossing the threshold for significant ownership. This type of filing is categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2024-01-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is used to disclose changes in share ownership by major shareholders or insiders. In the provided taxonomy, 'Major Shareholding Notification' (MRQ) is the most appropriate category for disclosures regarding significant share ownership changes and thresholds, while 'Director's Dealing' (DIRS) is typically for individual directors. Given the entity is a corporate major shareholder (Bio Solution) reporting a significant stake (15.22%) in Helixmith, MRQ is the correct classification.
2024-01-04 Korean
기타시장안내(연구개발 우수기업 매출액 특례적용 관련)
Regulatory Filings Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange (KRX) regarding a company's compliance with specific listing rules (revenue exemption for R&D companies). It does not fit into specific categories like financial reports, dividends, or M&A. As it is a general regulatory announcement regarding market listing status, it falls under the RNS (Regulatory Filings) category.
2024-01-04 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (임시주주총회). It does not contain the full proxy materials or the meeting results, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement and the lack of a specific category for 'Record Date Notice', it falls under the general regulatory filing category.
2024-01-04 Korean
주주총회소집결의(임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for the company Helixmith, detailing the date, time, location, and agenda items (such as the appointment of new directors). This type of document is a standard proxy solicitation or meeting notice provided to shareholders to inform them of an upcoming vote, which falls under the Proxy Solicitation & Information Statement category.
2024-01-04 Korean
투자판단관련주요경영사항(임상시험결과)(통증을 동반한 당뇨병성 신경병증(DPN) 치료제(Engensis: VM202) 임상시험 3상 (3-2, 3-2b) Topline Data 수령)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Helixmith) submitted to the KRX (Korea Exchange). It details the results of a clinical trial (Topline Data for Engensis/VM202). In the context of financial reporting, announcements regarding clinical trial outcomes, regulatory approvals, or significant business developments that do not fit into specific categories like 'Earnings Release' or 'Annual Report' are classified as 'Regulatory Filings' (RNS).
2024-01-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.